Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-Fibrinolytic Drugs are used to prevent or reduce bleeding in patients with certain medical conditions. Sri Lanka, a country in South Asia, has seen a steady growth in the Anti-Fibrinolytic Drugs market in recent years.
Customer preferences: The demand for Anti-Fibrinolytic Drugs in Sri Lanka is driven by the increasing prevalence of bleeding disorders and trauma cases. Patients with hemophilia and other bleeding disorders require these drugs to prevent excessive bleeding. Additionally, there is a growing awareness among healthcare professionals and patients about the benefits of these drugs, which has further boosted demand.
Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Sri Lanka is the increasing use of generic drugs. Generic drugs are cheaper than branded drugs and are becoming increasingly popular among patients due to their affordability. This has led to increased competition among drug manufacturers, resulting in lower prices.Another trend in the market is the shift towards more efficient and effective drugs. Newer drugs with better safety profiles and fewer side effects are being developed, which has led to increased adoption among healthcare professionals and patients.
Local special circumstances: Sri Lanka has a well-established healthcare system, which has contributed to the growth of the Anti-Fibrinolytic Drugs market. The government provides free healthcare to its citizens, which has made these drugs more accessible to the general population. Additionally, the country has a large population of elderly people who are more prone to bleeding disorders, which has further increased demand.
Underlying macroeconomic factors: The Sri Lankan economy has been growing steadily in recent years, which has led to increased healthcare spending. This has resulted in better access to healthcare services and drugs, including Anti-Fibrinolytic Drugs. Additionally, the government has implemented policies to encourage foreign investment in the pharmaceutical sector, which has led to increased competition and innovation in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
